Skip to main content
Erschienen in: Rheumatology International 4/2016

01.04.2016 | Original Article - Biomarkers

Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease

verfasst von: Mounika Reddy, Surjit Singh, Amit Rawat, Avinash Sharma, Deepti Suri, Manoj Kumar Rohit

Erschienen in: Rheumatology International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The diagnosis of Kawasaki disease (KD), a common pediatric vasculitis, is based solely on clinical criteria. There is a need for a robust laboratory marker that can help differentiate KD from other acute, febrile, childhood illnesses and also to predict cardiac involvement. We conducted a cross-sectional study of 25 consecutive patients admitted with diagnosis of KD from January 2013 to April 2014 and compared them with age- and sex-matched febrile controls. We studied the serum pro-brain natriuretic peptide (ProBNP) [ProBNP and N-terminal pro-B-type natriuretic peptide (NT-ProBNP) levels], a marker of myocardial dysfunction, in children with KD in acute and convalescent phases of disease. These levels were also estimated in febrile controls for comparison. The ProBNP (ProBNP and NT-ProBNP) levels were much higher in the acute phase of the KD patients compared to levels in the convalescent phase of KD (p = 0.000014). Similarly, the levels in the acute phase were higher when compared to the age- and sex-matched febrile controls (p = 0.000126). The receiver operating curve (ROC) analysis for the ProBNP levels in the acute phase of KD yielded an area under the curve of 0.954 ± 0.034 (p < 0.000, 95 % CI 0.886–1.0). Based on ROC analysis, a cutoff of 1025 pg/mL for ProBNP levels in the acute phase of KD had 88 % sensitivity and 96 % specificity for the diagnosis of KD. A lower cut-off of 514 pg/mL yielded a 100 % sensitivity and 80 % specificity for the diagnosis of KD. The ProBNP levels were higher in those with coronary artery abnormalities (CAA) compared to those without CAA in both acute (p = 0.013) and convalescent (p = 0.045) phases. ProBNP levels may be used as a surrogate marker for the differentiation of KD from other febrile, infectious illnesses and may also predict the involvement of coronary arteries.
Literatur
1.
Zurück zum Zitat Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the Young, American heart association. Circulation 110(17):2747–2771CrossRefPubMed Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC et al (2004) Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the Young, American heart association. Circulation 110(17):2747–2771CrossRefPubMed
2.
Zurück zum Zitat Son MBF, Newburger JW (2013) Kawasaki disease. Pediatr Rev Am Acad Pediatr 34(4):151–162CrossRef Son MBF, Newburger JW (2013) Kawasaki disease. Pediatr Rev Am Acad Pediatr 34(4):151–162CrossRef
3.
Zurück zum Zitat Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O et al (1986) Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 7(1):3–9CrossRefPubMed Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O et al (1986) Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 7(1):3–9CrossRefPubMed
4.
Zurück zum Zitat Duarte R, Cisneros S, Fernandez G, Castellon D, Cattani C, Melo CA et al (2010) Kawasaki disease: a review with emphasis on cardiovascular complications. Insights Imaging 1(4):223–231CrossRefPubMedPubMedCentral Duarte R, Cisneros S, Fernandez G, Castellon D, Cattani C, Melo CA et al (2010) Kawasaki disease: a review with emphasis on cardiovascular complications. Insights Imaging 1(4):223–231CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Cimaz R, Sundel R (2009) Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol 23(5):689–697CrossRefPubMed Cimaz R, Sundel R (2009) Atypical and incomplete Kawasaki disease. Best Pract Res Clin Rheumatol 23(5):689–697CrossRefPubMed
6.
Zurück zum Zitat Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C et al (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30(6):810–817CrossRefPubMed Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C et al (2009) Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 30(6):810–817CrossRefPubMed
7.
Zurück zum Zitat Takahashi M (1989) Myocarditis in Kawasaki syndrome. A minor villain? Circulation 79(6):1398–1400CrossRefPubMed Takahashi M (1989) Myocarditis in Kawasaki syndrome. A minor villain? Circulation 79(6):1398–1400CrossRefPubMed
8.
Zurück zum Zitat Tsai S-H, Lin Y-Y, Chu S-J, Hsu C-W, Cheng S-M (2010) Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 51(2):151–163CrossRefPubMedPubMedCentral Tsai S-H, Lin Y-Y, Chu S-J, Hsu C-W, Cheng S-M (2010) Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 51(2):151–163CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJJT (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 93(5):603–607CrossRefPubMed Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJJT (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 93(5):603–607CrossRefPubMed
10.
Zurück zum Zitat Dallaire F, Dahdah N (2011) New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 24(1):60–74CrossRef Dallaire F, Dahdah N (2011) New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 24(1):60–74CrossRef
11.
Zurück zum Zitat Abstracts of the 10th International Kawasaki Disease Symposium (February 7–10, 2012) Kyoto, Japan. Pediatr Int Off J Jpn Pediatr Soc. 54(Suppl 1):38–142 Abstracts of the 10th International Kawasaki Disease Symposium (February 7–10, 2012) Kyoto, Japan. Pediatr Int Off J Jpn Pediatr Soc. 54(Suppl 1):38–142
12.
Zurück zum Zitat Singh S, Aulakh R, Bhalla AK, Suri D, Manojkumar R, Narula N et al (2011) Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child 96(2):137–140CrossRefPubMed Singh S, Aulakh R, Bhalla AK, Suri D, Manojkumar R, Narula N et al (2011) Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child 96(2):137–140CrossRefPubMed
13.
Zurück zum Zitat Singh S, Aulakh R (2010) Kawasaki disease and Henoch Schonlein purpura: changing trends at a tertiary care hospital in north India (1993–2008). Rheumatol Int 30(6):771–774CrossRefPubMed Singh S, Aulakh R (2010) Kawasaki disease and Henoch Schonlein purpura: changing trends at a tertiary care hospital in north India (1993–2008). Rheumatol Int 30(6):771–774CrossRefPubMed
14.
Zurück zum Zitat Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341–347CrossRefPubMed Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE et al (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315(6):341–347CrossRefPubMed
15.
Zurück zum Zitat Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96(6):1057–1061PubMed Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96(6):1057–1061PubMed
16.
Zurück zum Zitat De Rosa G, Pardeo M, Rigante D (2007) Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci 11(5):301–308PubMed De Rosa G, Pardeo M, Rigante D (2007) Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci 11(5):301–308PubMed
17.
Zurück zum Zitat Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R et al (2010) Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int 30(6):841–846CrossRefPubMed Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R et al (2010) Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int 30(6):841–846CrossRefPubMed
18.
Zurück zum Zitat Burns JC, Newburger JW (2012) Genetics insights into the pathogenesis of Kawasaki disease. Circ Cardiovasc Genet 5(3):277–278CrossRefPubMed Burns JC, Newburger JW (2012) Genetics insights into the pathogenesis of Kawasaki disease. Circ Cardiovasc Genet 5(3):277–278CrossRefPubMed
19.
Zurück zum Zitat Burgner D, Harnden A (2005) Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis IJID Off Publ Int Soc Infect Dis 9(4):185–194 Burgner D, Harnden A (2005) Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis IJID Off Publ Int Soc Infect Dis 9(4):185–194
20.
Zurück zum Zitat Principi N, Rigante D, Esposito S (2013) The role of infection in Kawasaki syndrome. J Infect 67(1):1–10CrossRefPubMed Principi N, Rigante D, Esposito S (2013) The role of infection in Kawasaki syndrome. J Infect 67(1):1–10CrossRefPubMed
21.
Zurück zum Zitat Dahdah N (2010) Not just coronary arteritis, Kawasaki disease is a myocarditis, too. J Am Coll Cardiol 55(14):1507–1508CrossRefPubMed Dahdah N (2010) Not just coronary arteritis, Kawasaki disease is a myocarditis, too. J Am Coll Cardiol 55(14):1507–1508CrossRefPubMed
22.
Zurück zum Zitat Yutani C, Go S, Kamiya T, Hirose O, Misawa H, Maeda H et al (1981) Cardiac biopsy of Kawasaki disease. Arch Pathol Lab Med 105(9):470–473PubMed Yutani C, Go S, Kamiya T, Hirose O, Misawa H, Maeda H et al (1981) Cardiac biopsy of Kawasaki disease. Arch Pathol Lab Med 105(9):470–473PubMed
23.
Zurück zum Zitat Kao CH, Hsieh KS, Chen YC, Wang YL, Wang SJ, Yeh SH (1995) Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease. Clin Nucl Med 20(9):813–816CrossRefPubMed Kao CH, Hsieh KS, Chen YC, Wang YL, Wang SJ, Yeh SH (1995) Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease. Clin Nucl Med 20(9):813–816CrossRefPubMed
24.
Zurück zum Zitat Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L et al (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30(1):3–8CrossRefPubMed Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L et al (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30(1):3–8CrossRefPubMed
25.
Zurück zum Zitat Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 42(3):241–248CrossRef Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M (2000) Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 42(3):241–248CrossRef
26.
Zurück zum Zitat Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K et al (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26(4):425–430CrossRefPubMed Kurotobi S, Kawakami N, Shimizu K, Aoki H, Nasuno S, Takahashi K et al (2005) Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease. Pediatr Cardiol 26(4):425–430CrossRefPubMed
27.
Zurück zum Zitat Kishimoto S, Suda K, Teramachi Y, Nishino H, Kudo Y, Ishii H et al (2011) Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 53(5):736–741CrossRef Kishimoto S, Suda K, Teramachi Y, Nishino H, Kudo Y, Ishii H et al (2011) Increased plasma type B natriuretic peptide in the acute phase of Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 53(5):736–741CrossRef
28.
Zurück zum Zitat Sun Y-P, Wang W-D, Zheng X-C, Wang J-J, Ma S-C, Xu Y-J (2010) Levels of serum brain natriuretic peptide and the correlation to heart function in children with Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi Chin J Contemp Pediatr 12(3):169–171 Sun Y-P, Wang W-D, Zheng X-C, Wang J-J, Ma S-C, Xu Y-J (2010) Levels of serum brain natriuretic peptide and the correlation to heart function in children with Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi Chin J Contemp Pediatr 12(3):169–171
29.
Zurück zum Zitat Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP (2007) The integration of BNP and NT-ProBNP into clinical medicine. Swiss Med Wkly 137(1–2):4–12PubMed Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP (2007) The integration of BNP and NT-ProBNP into clinical medicine. Swiss Med Wkly 137(1–2):4–12PubMed
30.
Zurück zum Zitat Tang WHW (2007) B-type natriuretic peptide: a critical review. Congest Heart Fail Greenwich Conn 13(1):48–52CrossRef Tang WHW (2007) B-type natriuretic peptide: a critical review. Congest Heart Fail Greenwich Conn 13(1):48–52CrossRef
31.
Zurück zum Zitat Steiner J, Guglin M (2008) BNP or NTProBNP? A clinician’s perspective. Int J Cardiol 129(1):5–14CrossRefPubMed Steiner J, Guglin M (2008) BNP or NTProBNP? A clinician’s perspective. Int J Cardiol 129(1):5–14CrossRefPubMed
32.
Zurück zum Zitat Iwashima S, Ishikawa T (2013) B-type natriuretic peptide and N-terminal ProBNP in the acute phase of Kawasaki disease. World J Pediatr WJP 9(3):239–244CrossRefPubMed Iwashima S, Ishikawa T (2013) B-type natriuretic peptide and N-terminal ProBNP in the acute phase of Kawasaki disease. World J Pediatr WJP 9(3):239–244CrossRefPubMed
33.
Zurück zum Zitat Sato S, Kawashima H, Kashiwagi Y, Hoshika A (2013) Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Int J Rheum Dis 16(2):168–172CrossRefPubMed Sato S, Kawashima H, Kashiwagi Y, Hoshika A (2013) Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients. Int J Rheum Dis 16(2):168–172CrossRefPubMed
34.
Zurück zum Zitat Moran AM, Newburger JW, Sanders SP, Parness IA, Spevak PJ, Burns JC et al (2000) Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. Am Heart J 139(2 Pt 1):217–223PubMed Moran AM, Newburger JW, Sanders SP, Parness IA, Spevak PJ, Burns JC et al (2000) Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. Am Heart J 139(2 Pt 1):217–223PubMed
35.
Zurück zum Zitat Sato YZ, Molkara DP, Daniels LB, Tremoulet AH, Shimizu C, Kanegaye JT et al (2013) Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 164(1):58–63CrossRefPubMedPubMedCentral Sato YZ, Molkara DP, Daniels LB, Tremoulet AH, Shimizu C, Kanegaye JT et al (2013) Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol 164(1):58–63CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Cho SY, Kim Y, Cha S-H, Suh J-T, Han MY, Lee HJ (2011) Adjuvant laboratory marker of Kawasaki disease; NT-ProBNP or hs-CRP? Ann Clin Lab Sci 41(4):360–363PubMed Cho SY, Kim Y, Cha S-H, Suh J-T, Han MY, Lee HJ (2011) Adjuvant laboratory marker of Kawasaki disease; NT-ProBNP or hs-CRP? Ann Clin Lab Sci 41(4):360–363PubMed
37.
Zurück zum Zitat McNeal-Davidson A, Fournier A, Spigelblatt L, Saint-Cyr C, Mir TS, Nir A et al (2012) Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 54(5):627–633CrossRef McNeal-Davidson A, Fournier A, Spigelblatt L, Saint-Cyr C, Mir TS, Nir A et al (2012) Value of amino-terminal pro B-natriuretic peptide in diagnosing Kawasaki disease. Pediatr Int Off J Jpn Pediatr Soc 54(5):627–633CrossRef
38.
Zurück zum Zitat Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD et al (2011) Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 158(5):831–835CrossRefPubMedPubMedCentral Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD et al (2011) Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 158(5):831–835CrossRefPubMedPubMedCentral
Metadaten
Titel
Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease
verfasst von
Mounika Reddy
Surjit Singh
Amit Rawat
Avinash Sharma
Deepti Suri
Manoj Kumar Rohit
Publikationsdatum
01.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 4/2016
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3430-6

Weitere Artikel der Ausgabe 4/2016

Rheumatology International 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.